From gliadin deamidation and HLA-DQ2/DQ8 peptide presentation to tTG-IgA serology, Marsh grading, and the 2–5 year mucosal recovery window — a mechanistic guide to celiac disease and non-celiac gluten sensitivity.
Celiac disease is not a food allergy. It is a chronic, immune-mediated enteropathy triggered by dietary gluten — the storage protein complex of wheat, barley, and rye — in genetically susceptible individuals. The cascade from a piece of bread to flattened villi involves a precise sequence of molecular events.
Gliadin, the alcohol-soluble fraction of gluten, is resistant to full proteolytic digestion. Immunogenic peptide fragments — particularly the 33-mer gliadin peptide — survive luminal digestion and cross the intestinal epithelium, primarily via transcellular and paracellular routes. In celiac patients, upregulation of the protein zonulin loosens tight junctions, increasing paracellular permeability and allowing more gliadin to penetrate the lamina propria.
Once in the subepithelial space, gliadin peptides encounter tissue transglutaminase 2 (tTG2), an enzyme that catalyzes deamidation — converting glutamine residues to glutamate. This biochemical modification dramatically increases the affinity of gliadin peptides for HLA-DQ2 and HLA-DQ8 molecules on the surface of antigen-presenting cells (APCs). Deamidated gliadin is the key that fits the autoimmune lock.
The HLA-DQ2 (specifically the DQ2.5 heterodimer encoded by HLA-DQA1*05 and HLA-DQB1*02) and HLA-DQ8 (DQA1*03/DQB1*03:02) molecules present deamidated gliadin peptides to CD4+ T helper cells in the lamina propria. This interaction — gliadin peptide in the groove of DQ2/DQ8, recognized by T-cell receptors — is the immunological ignition point.
Crucially, HLA-DQ2/DQ8 are necessary but not sufficient. Over 30% of the general population carries DQ2 or DQ8, yet only ~1% develops celiac — pointing to additional genetic loci (non-HLA genes including IL-2/IL-21, RGS1, TAGAP) and environmental triggers (gut infections, formula feeding timing, microbiome composition).
Activated CD4+ T cells polarize toward a Th1 inflammatory phenotype, releasing pro-inflammatory cytokines including interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), and interleukin-15 (IL-15). This cytokine milieu drives:
The Marsh-Oberhuber classification system grades duodenal biopsy findings:
| Marsh Grade | Histological Finding | IEL/100 Enterocytes | Clinical Significance |
|---|---|---|---|
| 0 Normal | Normal architecture | <25 | Not celiac |
| 1 Infiltrative | Increased IELs only | ≥25 | Latent celiac or other causes |
| 2 Hyperplastic | IEL + crypt hyperplasia | ≥25 | Uncommon; requires correlation |
| 3a Partial VA | Partial villous atrophy | ≥25 | Diagnostic for active celiac |
| 3b Subtotal VA | Subtotal villous atrophy | ≥25 | Active celiac |
| 3c Total VA | Complete villous flattening | ≥25 | Severe active celiac |
Marsh 3 (any subgrade) in the appropriate clinical context confirms celiac disease. Marsh 1 is non-specific — it appears in SIBO, tropical sprue, Helicobacter pylori infection, and other enteropathies.
Celiac disease presents across a spectrum from overt gastrointestinal symptoms to entirely silent disease discovered on incidental biopsy. The classical textbook presentation is now the minority.
This is how the majority of celiac patients present today, particularly adults:
DH is the cutaneous manifestation of celiac disease — an intensely pruritic, blistering rash distributed symmetrically on elbows, knees, buttocks, and scalp. It is caused by IgA immune complex deposition in the dermis. Nearly all DH patients have intestinal celiac disease on biopsy, though often asymptomatic gastrointestinally. Skin biopsy with direct immunofluorescence for IgA is diagnostic. DH resolves on a strict gluten-free diet and, if needed, responds to dapsone.
RCD is defined as persistent symptoms and villous atrophy despite strict adherence to a gluten-free diet for >12 months, after exclusion of other causes. It affects ~1–2% of celiac patients. RCD Type 2 involves an aberrant intraepithelial lymphocyte clone and carries significant risk of progression to enteropathy-associated T-cell lymphoma (EATL), a rare but serious complication.
A confident celiac diagnosis requires a systematic approach. The current gold standard combines serological testing with duodenal biopsy — both performed while the patient is actively consuming gluten.
Anti-tissue transglutaminase IgA (tTG-IgA) is the recommended first-line test, with ~95% sensitivity and ~98% specificity in adults on a gluten-containing diet. Results are reported as a ratio to the upper limit of normal (ULN). Values ≥10× ULN have very high positive predictive value and, in some guidelines (ESPGHAN 2020 for children), may allow diagnosis without biopsy if confirmed by EMA-IgA.
Approximately 2–3% of the general population has selective IgA deficiency — and the rate is higher in celiac patients (~1 in 40). In IgA deficiency, tTG-IgA and EMA-IgA will be falsely negative. A total serum IgA must be measured alongside tTG-IgA. If IgA is deficient, switch to IgG-based assays: deamidated gliadin peptide IgG (DGP-IgG) or tTG-IgG.
Anti-endomysial IgA (EMA-IgA) is highly specific (>98%) for celiac disease. It is an indirect immunofluorescence assay on monkey esophagus or human umbilical cord tissue, detecting antibodies against reticulin/endomysial connective tissue — the same target as tTG2 but visualized differently. EMA is confirmatory when tTG-IgA is borderline or intermediate.
Upper endoscopy with at least 4 biopsies from the second/third part of the duodenum plus 1–2 from the duodenal bulb (per ACG 2023 guidelines) remains the histological gold standard. Patchy lesion distribution means inadequate sampling can miss disease. The pathologist grades biopsies using the Marsh-Oberhuber system.
This is a critical clinical point: both serology and histology normalize on a gluten-free diet. A patient who has already started a GFD will show false-negative results. The correct sequence is:
HLA typing does not confirm celiac — it excludes it. A negative result (neither DQ2 nor DQ8 present) makes celiac disease extremely unlikely (<1% probability) and can spare patients from invasive workup or gluten challenge. Genetic testing is recommended for:
The gluten-free diet is the only evidence-based treatment for celiac disease. There are no FDA-approved drugs, no supplements that permit gluten consumption, and no tolerance that develops over time. But the GFD is both a treatment and a long journey — mucosal healing is measured in years, not weeks.
Notably, children heal significantly faster than adults — most pediatric patients show complete histological normalization within 1–2 years. Adult mucosal healing is slower due to slower intestinal cell turnover and longer cumulative immune activation.
Up to 30–40% of adults show persistent Marsh 3 lesions at 2 years despite reported GFD adherence. The most common causes:
The Codex Alimentarius standard and FDA definition for "gluten-free" is <20 parts per million (ppm) of gluten. This threshold was established based on the maximum level shown not to cause intestinal damage in the majority of celiac patients in clinical trials. However, highly sensitive individuals may react at lower levels, and cumulative daily intake matters more than per-serving concentration.
Three distinct conditions cause adverse reactions to gluten/wheat, with very different underlying mechanisms, risk profiles, and management approaches. Conflating them leads to misdiagnosis and inappropriate treatment.
Non-celiac gluten sensitivity (NCGS) was formally characterized by Fasano and colleagues in a 2011 consensus paper (Fasano A, et al. Ann NY Acad Sci. 2012) as a condition distinct from celiac disease and wheat allergy, characterized by:
NCGS symptoms include bloating, abdominal pain, loose stools, fatigue, brain fog, headache, and joint pain — substantially overlapping with celiac and IBS. Prevalence estimates range from 0.5% to 6% of the population, though methodological challenges (nocebo effect, FODMAP confounding) make accurate prevalence uncertain.
Fasano's group proposed that NCGS involves elevated zonulin — a protein regulating tight junction permeability — leading to increased intestinal permeability ("leaky gut") without the autoimmune cascade of celiac. Innate immunity (rather than adaptive Th1 immunity) is implicated, with activation of toll-like receptors (TLR2/TLR4) by gliadin and amylase-trypsin inhibitors (ATIs) in wheat. The zonulin hypothesis remains an active area of research with ongoing debate about causality vs. correlation.
| Feature | Celiac Disease | NCGS | Wheat Allergy |
|---|---|---|---|
| Mechanism | Autoimmune (adaptive Th1) | Innate immune / unclear | IgE-mediated allergy |
| HLA Risk Genes | DQ2/DQ8 (99%+) | DQ2/DQ8 (~50%) | Not required |
| tTG-IgA | Positive (active disease) | Negative | Negative |
| Intestinal Biopsy | Villous atrophy (Marsh 3) | Normal or Marsh 1 | Normal |
| Wheat IgE | Negative | Negative | Positive |
| Symptom Onset | Hours to days | Hours to days | Minutes to 2 hours |
| Complications | Lymphoma, osteoporosis, infertility | Currently unknown | Anaphylaxis (rare) |
| Diagnosis | Serology + biopsy | Exclusion of above | Skin prick / IgE RAST |
A landmark 2013 double-blind crossover trial (Biesiekierski et al., Gastroenterology) found that when FODMAPs (fermentable oligosaccharides, disaccharides, monosaccharides, and polyols — which are abundant in wheat) were controlled, specific effects of gluten in self-identified NCGS patients disappeared. This suggests that in many people labeled as NCGS, the actual trigger is fructans (a FODMAP in wheat), not gluten protein itself. A low-FODMAP diet trial should be considered before committing to a lifelong strict GFD in non-celiac patients.
| Study / Guideline | Finding | Clinical Implication |
|---|---|---|
| Sollid et al. (1989) — J Exp Med | HLA-DQ2 identified as primary celiac risk allele; DQ2/DQ8 present in >99% of celiac patients | HLA testing can exclude celiac with >99% NPV; no need for gluten challenge if DQ2/DQ8 negative |
| Dieterich et al. (1997) — Nature Medicine | tTG2 identified as the autoantigen in celiac disease; anti-tTG antibodies are diagnostic | tTG-IgA is now the first-line serological test with ~95% sensitivity |
| Rubio-Tapia et al. (2010) — Gastroenterology | Mucosal healing achieved in 66% of adults at 2 years and 82% at 5 years on strict GFD | Histological follow-up at 2 years is clinically relevant; full healing is a multi-year process |
| Biesiekierski et al. (2013) — Gastroenterology | In low-FODMAP conditions, NCGS patients showed no specific response to gluten | FODMAPs (fructans) may be the true trigger in many self-identified NCGS patients |
| ESPGHAN Guidelines (2020) — J Pediatr Gastroenterol Nutr | Children with tTG-IgA ≥10× ULN + positive EMA can be diagnosed without biopsy | Biopsy may be avoided in symptomatic children with very high serology; biopsy still required in adults |
Evidence-informed steps for diagnosed celiac patients beginning the healing journey. Always work with your gastroenterologist.
Remove all wheat, barley, rye, and cross-contaminated oats. Use dedicated GF cookware. No "small amounts" — even 50mg/day (less than 1/8 tsp flour) can perpetuate intestinal damage in celiac disease.
Replace: wooden cutting boards, wooden spoons, scratched non-stick pans, colanders, and shared toasters. Dedicated GF zones in shared kitchens are essential. Shared butter/condiment jars are contamination vectors.
Test at diagnosis: iron/ferritin, folate, B12, vitamin D, calcium, magnesium, zinc, and copper. Supplementation guided by lab results — do not supplement blindly. Most deficiencies resolve with GFD + targeted supplementation within 12 months.
Glutamine is the primary fuel source for enterocytes (intestinal lining cells). Early research and clinical practice support 5–10g/day glutamine supplementation to accelerate mucosal repair. Look for products with no gluten-containing fillers.
Dipeptidyl peptidase-IV (DPP-IV) enzymes partially hydrolyze gliadin peptides, potentially reducing immune activation from accidental gluten exposure. They do not enable intentional gluten consumption but may mitigate the harm of cross-contamination events during the healing phase.
Celiac disease is associated with dysbiosis — reduced Lactobacillus and Bifidobacterium, elevated Bacteroides and Clostridium. A diverse, whole-food GFD (emphasizing GF whole grains like buckwheat, quinoa, and millet) and probiotic supplementation support microbiome restoration.
tTG-IgA should be checked at 6 months and 12 months after diagnosis, then annually. Persistent elevation suggests ongoing gluten exposure. Rising tTG-IgA after normalization is a red flag for accidental contamination or dietary drift.
ACG guidelines recommend follow-up biopsy at 1–2 years for adults with initial Marsh 3 lesions to confirm histological healing, particularly before introducing oats or in patients with persistent symptoms. Do not assume healing from symptom resolution alone.
These are not treatments for celiac disease. The only treatment is a strict gluten-free diet. These supplements target common deficits and mechanisms in gut repair during the healing phase.